Recruiting
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring - IM047-003
Opdateret:
17 april, 2025
|
ClinicalTrials.gov
Køn
Aldersinterval
Beliggenhed(er)
Recruiting
Inclusion Criteria: - Diagnosis of Multiple sclerosis (MS) - Currently or recently pregnant - Reside in a country where ozanimod is prescribed for treatment of MS Exclusion Criteria: - Diagnostic prenatal test results known prior to first contact with the Registry Coordination Center (RCC) - Exposure to known teratogens and/or investigational medications during pregnancy Other protocol-defined inclusion/exclusion criteria apply
Hvis du vil rapportere en bivirkning, kan du indberette direkte til Lægemiddelstyrelsen via hjemmesiden www.meldenbivirkning.dk
Vi anbefaler at du også kontakter BMS for at rapportere bivirkninger.
Bivirkninger og andre rapporterbare begivenheder er defineret her
Rapporter bivirkninger eller klager over produktkvalitet: Medicinsk information
466-DK-2200001